Valenza C - Search Results

1

The triple negative breast cancer drugs graveyard: a review of failed clinical trials 2017-2022.

Taurelli Salimbeni B, Corvaja C, Valenza C, Zagami P, Curigliano G. Taurelli Salimbeni B, et al. Among authors: valenza c. Expert Opin Investig Drugs. 2022 Nov;31(11):1203-1226. doi: 10.1080/13543784.2022.2151433. Epub 2022 Dec 22. Expert Opin Investig Drugs. 2022. PMID: 36413823 Review.

2

Complex Differential Diagnosis between Primary Breast Cancer and Breast Metastasis from EGFR-Mutated Lung Adenocarcinoma: Case Report and Literature Review.

Valenza C, Porta FM, Rappa A, Guerini-Rocco E, Viale G, Barberis M, de Marinis F, Curigliano G, Catania C. Valenza C, et al. Curr Oncol. 2021 Aug 31;28(5):3384-3392. doi: 10.3390/curroncol28050292. Curr Oncol. 2021. PMID: 34590588 Free PMC article. Review.

3

Cyclin dependent kinase 4/6 inhibitors in early breast cancer: what is the role of Ki-67?

Antonarelli G, Valenza C, Mayer EL, Loibl S, Curigliano G. Antonarelli G, et al. Among authors: valenza c. Lancet Oncol. 2022 Mar;23(3):325-328. doi: 10.1016/S1470-2045(21)00756-7. Lancet Oncol. 2022. PMID: 35240079 No abstract available.

4

Emerging treatment landscape of non-muscle invasive bladder cancer.

Valenza C, Antonarelli G, Giugliano F, Aurilio G, Verri E, Briganti A, Curigliano G, Necchi A. Valenza C, et al. Expert Opin Biol Ther. 2022 Jun;22(6):717-734. doi: 10.1080/14712598.2022.2082869. Epub 2022 May 31. Expert Opin Biol Ther. 2022. PMID: 35634893 Review.

5

Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Moving Into a New Era.

Gion M, Trapani D, Cortés A, Valenza C, Lin N, Cortés J, Curigliano G. Gion M, et al. Among authors: valenza c. Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-11. doi: 10.1200/EDBK_351222. Am Soc Clin Oncol Educ Book. 2022. PMID: 35671434 Free article.

6

Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe?

Corti C, Antonarelli G, Valenza C, Nicolò E, Rugo H, Cortés J, Harbeck N, Carey LA, Criscitiello C, Curigliano G. Corti C, et al. Among authors: valenza c. Eur J Cancer. 2022 Aug;171:25-42. doi: 10.1016/j.ejca.2022.04.039. Epub 2022 Jun 11. Eur J Cancer. 2022. PMID: 35696887 Review.

7

Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?

Giugliano F, Valenza C, Tarantino P, Curigliano G. Giugliano F, et al. Among authors: valenza c. Expert Opin Investig Drugs. 2022 Aug;31(8):855-874. doi: 10.1080/13543784.2022.2095260. Epub 2022 Jul 6. Expert Opin Investig Drugs. 2022. PMID: 35762248

8

Circulating tumour DNA dynamics for assessment of molecular residual disease and for intercepting resistance in breast cancer.

Valenza C, Trapani D, Curigliano G. Valenza C, et al. Curr Opin Oncol. 2022 Nov 1;34(6):595-605. doi: 10.1097/CCO.0000000000000905. Epub 2022 Sep 7. Curr Opin Oncol. 2022. PMID: 36083118 Review.

9

Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives.

Valenza C, Rizzo G, Passalacqua MI, Boldrini L, Corti C, Trapani D, Curigliano G. Valenza C, et al. Ther Adv Med Oncol. 2023 Jan 19;15:17588359221146129. doi: 10.1177/17588359221146129. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 36743524 Free PMC article. Review.

10

Tumor Infiltrating Lymphocytes across Breast Cancer Subtypes: Current Issues for Biomarker Assessment.

Valenza C, Taurelli Salimbeni B, Santoro C, Trapani D, Antonarelli G, Curigliano G. Valenza C, et al. Cancers (Basel). 2023 Jan 26;15(3):767. doi: 10.3390/cancers15030767. Cancers (Basel). 2023. PMID: 36765724 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

49 results

Search Page

Filters